Lacosamide Teva

Lacosamide, the active ingredient in Lacosamide Teva, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures and is used as adjunctive therapy in patients with epilepsy. GNH USA supplies Lacosamide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Focal epilepsy: improves overall seizure control as adjunctive treatment. - Adjunctive therapy for epilepsy: enhances effectiveness of other antiepileptic medications.

Lacosamide may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Dizziness: transient light‑headedness or imbalance. - Headache: mild to moderate pain in the head region. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Diplopia: double vision episodes. - Blurred vision: temporary visual clarity loss.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Respiratory depression: reduced breathing effort. - Anaphylaxis: acute allergic reaction with airway compromise. - Liver injury: elevated liver enzymes or hepatitis.

Before initiating Lacosamide therapy, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly. - Concomitant antiepileptic drugs: evaluate for additive CNS effects. - Pregnancy: risk unknown; weigh benefits against potential risks. - Breastfeeding: unknown safety; consider alternatives. - Driving and operating machinery: may cause dizziness; advise caution. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Lacosamide can interact with several medicines; categorize interactions by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., lamotrigine, topiramate): increase risk of CNS depression. - QT‑prolonging agents (e.g., quinidine, sotalol): may exacerbate cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): can raise lacosamide concentrations. - Diuretics: may alter serum electrolytes affecting cardiac safety. - Alcohol: can enhance dizziness and sedation; advise limited intake.